Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men

Hypertension

Volumn 30, Issue 2, 1997, Pages 240-246

  Price, Deborah A ^a   De'Oliveira, Jose Mario ^a   Fisher, Naomi D L ^a   Hollenberg, Norman K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aldosterone; Angiotensin II; Antihypertensive agents; Renal circulation; Renin

Indexed keywords

ANGIOTENSIN ANTAGONIST; EPROSARTAN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEMODYNAMICS; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; KIDNEY BLOOD FLOW; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALT INTAKE; SALT LOADING;

EID: 0030835676     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.2.240     Document Type: Article

References (48)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
2. Keane WF, Anderson S, Aurell M, deZeeuw D, Narins RG, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency: current experience and future directions. Ann Intern Med. 1989;111:503-516.
3. Schmieder RE, Martus P, Kingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta analysis of randomized double-blind studies. JAMA. 1996;275:1508-1513.
4. Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension. 1983;5(suppl III):III-36-III-42.
5. Farhy RD, Carretero OA, Hok L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 1993;72:1202-1210.
6. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Colch). 1994;87:567-574.
7. Danckwardt L, Shimizu I, Bonner G, Rettig R, Unger T. Converting enzyme inhibition in kinin-deficient brown Norway rats. Hypertension. 1990;16:429-435.
8. Zusman RM. Effects of converting enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid prostaglandin systems: correlation of chemical structure and biological activity. Am J Kidney Dis. 1987;10:13-23.
9. Riegger GA, Elsner D, Kromer EP. Circulatory and renal control by prostaglandins and renin in low cardiac output in dogs. Am J Physiol. 1989;256:H1079-H1086.
10. Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation. 1988;76(suppl I):I-64-I-73.
11. Wang YX, Gavras I, Lammek B, Bresnahan M, Gavras H. Effects of bradykinin and prostaglandin inhibition on systemic and regional hemodynamics in conscious normotensive rats. J Hypertens. 1991;9: 805-812.
12. Cordero PL, Fisher NE, Moore TJ, Gleason R, Williams GH, Hollenberg NK. Renal and endocrine response to a renin inhibitor, enalkiren, in normal renin humans. Hypertension. 1991;17:510-516.
13. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension. 1994;23: 44-51.
14. Fisher NDL, Hollenberg NK. Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther. 1995;57: 342-348.
15. Hollenberg NK, Fisher NDL. Renal circulation and blockade of the renin-angiotensin system: is angiotensin-converting enzyme inhibition the last word? Hypertension. 1995;26:602-609.
16. Kleinert HD, Rosenberg SH, Baker WR, Stein HH, Klinghofer V, Barlow J, Spina K, Polakowski J, Rovar P, Cohen J, Denissen J. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science. 1992;257:1940-1943.
17. El-Amrani A-IK, Menard J, Gonzales MF, Michel JB. Effects of blocking the angiotensin II receptor converting enzyme and renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol. 1993;22:231-239.
18. Timmermans PBMWM, Wang PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Sage JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
19. 2 receptors are in the spotlight. J Clin Invest. 1996;97:1787. Editorial.
20. Hollenberg NK, Meggs LG, Williams GH. Katz J, Garnie JD, Harrington DP, Sodium intake and renal responses to captopril in normal man and essential hypertension. Kidney Int. 1981;20: 240-245.
21. Conlin PR, Moore TJ, Williams GH, Hollenberg NK. Rapid modulation of renal and adrenal responsiveness to angiotensin II. Hypertension. 1993;22:832-838.
22. Rogacz S, Hollenberg NK, Williams GH. Role of angiotensin II in the hormonal, renal, and electrolyte response to sodium restriction. Hypertension. 1987;9:289-294.
23. Rogacz S, Williams GH, Hollenherg NK. Time course of enhanced adrenal responsiveness to angiotensin on a low-salt diet. Hypertension. 1990;15:376-380.
24. Emanuel R, Cain JP, Williams GH. Double antibody radioimmunoassay of renin activity and Ang II in human peripheral plasma. J Lab Clin Med. 1973;81:632-640.
25. Underwood RH, Williams GH. The simultaneous measurement of aldosterone, cortisol, and corticosterone in human peripheral plasma by displacement analysis. J Lab Clin Med. 1972;70:848-862.
26. Grabbs FE. Procedures for detecting outlying observations in samples. Technometrics. 1969;11:1-21.
27. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996;49:1787-1790.
28. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22: 339-347.
29. Burnier M, Pechere-Bertuschi A, Nussberger J, Waeber B, Brunner HR. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive system. Am J Kidney Dis. 1995;26:108-115.
30. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Waeber B, Brunner HR. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension. 1995;25:602-609.
31. Martinez F, Schmitt F, Nator S, Savoiu C, Lacour B, Madonna O, Grunfeld JP, Hannedouche T. Renal effects of losartan and enalapril alone and in combination in healthy volunteers. In: Proceedings of the Gainesville International Society of Nephrology. Jerusalem; 1993: 228.
32. Nakashima M, Vematsu T, Kosage K, Kanamura M. Pilot study of the uricosuric effect of Dup-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42: 333-335.
33. Sweet CS, Bradstreet DC, Berman RS, Jallard M, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens. 1994;7:1035-1040.
34. Burnier M, Waeber B, Brunner HR. Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects, J Hypertens. 1995;13(suppl):S23-S28.
35. Gansevoort R, DeZecuw D, DeJong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-867.
36. Anderson S. Renal effects of converting enzyme inhibitors in hypertension and diabetes. J Cardiovasc Pharmacol. 1990;3(suppl): S11-S15.
37. Bauer JH, Reams GP. Renal effects of angiotensin converting enzyme inhibitors in hypertension. Am J Med. 1986;81:19-27.
38. Hsueh WA, Anderson PW. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiol. 1993;72:14H-21H.
39. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992;42:1020-1029.
40. 2 and prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992;263:905-909.
41. Rao PS, Cavanagh D, Dietz JR, Marsden KA, O'Brien WF, Spaziani E. Dose-dependent effects of prostaglandin Dc on hemodynamic renal function and blood gas analyses. Am J Obstet Gynecol. 1987;156:843-851.
42. Heller J, Kramer HJ, Horacek V. The effect of kinin and prostaglandin inhibitors on the renal response to angiotensin-converting enzyme inhibition on micropuncture study in the dog. Pflugers Arch. 1994;427:219-224.
43. Allan DR, McKnight JA, Kifor I, Coletti CM, Hollenberg NK. Converting enzyme inhibition and renal tissue angiotensin II in the rat. Hypertension. 1994;24:516-522.
44. Lin C, Frishman WH. Renin inhibition: a novel therapy for cardiovascular disease. Am Heart J. 1996;131:1024-1034.
45. Cody RJ. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs. 1994;47:586-598.
46. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286-289.
47. Fluck RJ, Raine AE. ACE inhibitors in non-diabetic renal disease. Br Heart J. 1994;72:546-551.
48. Anderson S, Brenner BM. Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. Am J Hypertens. 1988;1:380S-383S.